---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-072713"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2026-11-10T21:06:42+00:00"
generated_at: "2026-11-10T21:09:42.691935+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine pegs Sept 30 cash at ~$61.2M preliminary, excluding $13.7M restricted

## Summary
- Preliminary unaudited cash, cash equivalents and short-term investments of approximately $61.2 million as of September 30, 2026; restricted cash of ~$13.7 million excluded.
- Company has not completed its quarter-end close for Q3 2026; warns actual results may differ materially from these management estimates.
- PricewaterhouseCoopers has not audited, reviewed, examined or compiled the preliminary figures and expresses no assurance on them.
- Complete results will be reported in the Form 10-Q for the quarter ended September 30, 2026; no duty to update the estimates.
- Updated November 2026 corporate presentation posted to the investor site; the Exhibit 99.1 text supplied here is truncated, so deck contents could not be verified.

## SEC filing metadata
- accession: 0001628280-26-072713
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2026-11-10T21:06:42+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828026072713/0001628280-26-072713-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828026072713/prme-20261110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-072713
- JSON: https://secwatch.observer/filing/0001628280-26-072713.json
- Plain text: https://secwatch.observer/filing/0001628280-26-072713.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.